Invention Grant
US07863437B2 RNA antagonist compounds for the modulation of PIK3CA expression
有权
用于调节PIK3CA表达的RNA拮抗剂化合物
- Patent Title: RNA antagonist compounds for the modulation of PIK3CA expression
- Patent Title (中): 用于调节PIK3CA表达的RNA拮抗剂化合物
-
Application No.: US12323744Application Date: 2008-11-26
-
Publication No.: US07863437B2Publication Date: 2011-01-04
- Inventor: Maj Hedtjarn
- Applicant: Maj Hedtjarn
- Applicant Address: US NJ Bridgewater DK Hoersholm
- Assignee: Enzon Pharmaceuticals, Inc.,Santaris Pharma A/S
- Current Assignee: Enzon Pharmaceuticals, Inc.,Santaris Pharma A/S
- Current Assignee Address: US NJ Bridgewater DK Hoersholm
- Agency: Lucas & Mercanti, LLP
- Main IPC: C07H21/04
- IPC: C07H21/04
Abstract:
The invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases (e.g., cancer). The invention provides therapeutic compositions that include the oligomers and methods for modulating the expression of PIK3CA using said oligomers, including methods of treatment.
Public/Granted literature
- US20090192110A1 RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION Public/Granted day:2009-07-30
Information query
